Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer

Vanderbilt University Medical Center

Status: Completed

Conditions: Ovarian Cancer

Treatments: Other: immunohistochemistry; Genetic: protein expression analysis

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT00900523

VU-VICC-IRB-060680

VU-VICC-GYN-0648

VICC GYN 0648

Details and patient eligibility

About

RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future.

PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.

Full description

OBJECTIVES:

• Determine the level of prostaglandin E_2 metabolite (PGE-M) in 24-hour urine samples collected prior to surgery or chemotherapy from patients with ovarian cancer.
• Determine cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) expression by western blot and immunohistochemistry (IHC) in ovarian tumor tissue samples and matched normal ovarian tissue samples, if available, from these patients.
• Correlate urine PGE-M levels with corresponding tissue COX-1 and COX-2 levels in urine and tissue samples from these patients.

OUTLINE: This is a pilot study.

Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E_2 metabolite (PGE-M).

Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.

Enrollment: 7 patients

Sex: Female

Ages: 17+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of known or suspected ovarian cancer
• Age greater than 17 years

Exclusion criteria

• Pregnant or nursing
• Taking steroids or non-steroidal anti-inflammatory drugs (NSAIDs) on a regular basis.

PRIOR CONCURRENT THERAPY:

• No concurrent chronic use of steroids or NSAIDs

Trial design

7 participants in 1 patient group

Known or suspected ovarian cancer

Description:

Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer

Treatment:

Genetic: protein expression analysis

Other: immunohistochemistry